| 30.10 21:00 | dpa-AFX: GNW-Adhoc: Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH |
| 21.10 14:30 | dpa-AFX: GNW-Adhoc: Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024 |
| 14.10 19:45 | dpa-AFX: GNW-Adhoc: Inventiva announces the availability of a prospectus in connection with its financing through the issuance of ordinary shares and pre-funded warrants |
| 14.10 08:35 | dpa-AFX: GNW-Adhoc: Inventiva announces Filing of 2024 Half-Year Report - Conditions for Accessing or Consulting the Report |
| 14.10 08:30 | dpa-AFX: GNW-Adhoc: Inventiva announces financing of up to ?348 million to advance the NATiV3 Phase 3 MASH study |
| 25.09 22:00 | dpa-AFX: GNW-Adhoc: Inventiva provides a corporate update and reports its unaudited 2024 first-half financial results |
| 31.07 22:00 | dpa-AFX: GNW-Adhoc: Inventiva Reports Preliminary 2024 First-Half Financial Information¹ |
| 25.07 22:00 | dpa-AFX: GNW-Adhoc: Inventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranor |
| 18.07 08:30 | dpa-AFX: GNW-Adhoc: Inventiva announces a ?20.1 million issuance of royalty certificates |
| 05.07 22:00 | dpa-AFX: GNW-Adhoc: Inventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial position |
| 21.06 22:05 | dpa-AFX: GNW-Adhoc: Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 20 June 2024 |
| 21.06 22:00 | dpa-AFX: GNW-Adhoc: Results of the votes of the Combined Shareholders' General Meeting of June 20, 2024 |
| 30.05 08:30 | dpa-AFX: GNW-Adhoc: Combined General Meeting of June 20, 2024 - Availability of the preparatory documents |
| 22.05 22:00 | dpa-AFX: GNW-Adhoc: Inventiva announces two scientific presentations at the EASL International Liver CongressT 2024 |
| 21.05 22:00 | dpa-AFX: GNW-Adhoc: Inventiva reports 2024 First Quarter Financial Information¹ and provides a corporate update |
| 16.05 22:00 | dpa-AFX: GNW-Adhoc: Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH |
| 13.05 08:30 | dpa-AFX: GNW-Adhoc: Inventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranor |
| 03.04 22:00 | dpa-AFX: GNW-Adhoc: Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F |
| 28.03 08:00 | dpa-AFX: GNW-Adhoc: Inventiva announces the nomination of Andre Turenne as Director |
| 27.03 21:00 | dpa-AFX: GNW-Adhoc: Inventiva reports its 2023 full-year results |
|
|
